Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. Dr. Mohamed brings over 20 years of experience as a Radiation Oncologist, clinical researcher, and biotechnology advisor.
Dr. Mohamed's expertise spans lung, breast, skin cancers, and sarcoma treatment at BC Cancer, with significant experience in stereotactic radiation delivery. He has led numerous clinical trials and served on research ethics boards and national committees. His role will involve providing strategic guidance on R&D initiatives and facilitating clinical and scientific collaboration.
Onco-Innovations (OTCQB:ONNVF) has signed a crucial agreement with Nucro-Technics to conduct IND-enabling preclinical studies for its lead drug candidate. The studies will focus on the company's PNKP inhibitor (NP/A83), which targets advanced-stage, PTEN- or SHP-1-deficient cancers.
The comprehensive testing program includes drug metabolism testing (ADME studies) and GLP-compliant safety studies required for regulatory approval. Nucro-Technics, a Toronto-based CRO with 55 years of experience, will evaluate the drug's bioavailability, biodistribution, pharmacokinetics, and safety profile to support future IND applications with both FDA and Health Canada.
The agreement represents a significant milestone toward initiating Phase I/II clinical trials, including validation of analytical methods and safety assessment of the novel polymer delivery system (mPEO-bPBCL).
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy provided a comprehensive update on the company's strategic developments and R&D progress during a special investor call. Key highlights include the advancement of their PNKP Inhibitor Technology with Dalton Pharma Services for preclinical testing, and progress in the PROmAI consortium with potential AstraZeneca participation.
The company has established a new research agreement with the University of Alberta and Cross Cancer Institute to study PNKP inhibition in glioblastoma multiforme. Following their February 2025 acquisition of Inka Health AI and May 2025 uplisting to Cboe Canada, Onco-Innovations continues to integrate AI capabilities into drug development through Inka's Synograph system.
Onco-Innovations (CBOE CA:ONCO) announced that its subsidiary, Inka Health, has received an Expression of Interest (EOI) from AstraZeneca to join as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium.
The PROmAI Consortium, led by Inka Health, aims to advance AI methodologies in oncology by combining real-world and clinical trial data with causal AI techniques. The initiative focuses on improving predictive modeling in cancer research, particularly during the transition from early- to late-phase clinical development.
AstraZeneca's involvement will include participation in the exploratory phase, encompassing joint planning discussions, project direction input, and strategic alignment around key use cases. Inka Health is currently in discussions with other global pharmaceutical companies for potential consortium participation.
Onco-Innovations Limited (OTCQB:ONNVF) has announced a special investors' conference call scheduled for Wednesday, July 2, 2025, at 2:00 p.m. PST/5:00 p.m. ET. The call will be hosted by CEO Thomas O'Shaughnessy.
Investors can participate through the conference link's 'Dial Me' feature or by calling toll-free numbers. Participants are encouraged to submit questions in advance to investors@oncoinnovations.com. The company will release a press release following the conference call.
Onco-Innovations (ONNVF) has initiated manufacturing of preclinical testing material for its PNKP inhibitor technology through Dalton Pharma Services. The project aims to produce 50 grams of their proprietary inhibitor A83B4C63 for preclinical studies and IND submission preparation.
Previous research from 2021 demonstrated promising results: the nanoparticle-formulated PNKP inhibitor significantly extended median survival in PTEN-deficient colorectal cancer-bearing mice to 60 days vs. 23 days in untreated controls. Additionally, when combined with radiation therapy, it enhanced tumor growth delay without significant toxicity to healthy tissues.
Onco-Innovations (ONNVF) has extended its marketing engagement with MCS Market Communication Service GmbH for online marketing services. The extended services include campaign creation, marketing materials production, and research and analytics. The program will run until June 30, 2025, or until budget exhaustion. Onco-Innovations has paid EUR 500,000 for this extension. The services will be delivered through digital channels, including Google Ads and native advertising. No securities were issued as compensation for these services.